Drugs / cPMP
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01894165 | Jun → Sep 2013 | autosomal recessive disease, sulfite oxidase deficiency due to molybdenum cofactor deficiency | Origin Biosciences | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00957749 | Aug 2009 → Apr 2010 | sulfite oxidase deficiency due to molybdenum cofactor deficiency type A | Orphatech Pharmaceuticals, GmbH | Withdrawn | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | cPMP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00957749 ↗ |
| Known as | ALXN1101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01894165 ↗ |
| Route | Intravenous | “Intravenous solution administered daily.” NCT00957749 ↗ |